Results 21 to 30 of about 50,152 (259)

Rural and urban differences in undersupply of buprenorphine provider availability in the United States, 2018

Addiction Science & Clinical Practice, 2022
Background Medications to treat opioid use disorder (OUD) including buprenorphine products are evidence-based and cost-effective tools for combating the opioid crisis.
Kevin P. Conway, Dalia Khoury, Rainer Hilscher, Arnie P. Aldridge, Stephanie J. Parker, Gary A. Zarkin   +5 more
doaj   +1 more source

Perioperative Buprenorphine Management and Postoperative Pain Outcomes: A Retrospective Study with Evidence-Based Recommendations

International Journal of Translational Medicine
The prevalence of patients on buprenorphine therapy presenting for elective surgery has increased. Buprenorphine is a widely used medication for the management of patients with chronic pain.
Amruta Desai, Shruti Parikh, Sergio Bergese   +2 more
doaj   +1 more source

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach

Addiction Science & Clinical Practice, 2020
Background The requirement for moderate withdrawal prior to initiation can be a barrier to buprenorphine/naloxone induction. Case presentation We aimed to use a microdosing regimen to initiate regular dosing of buprenorphine/naloxone in a high-risk ...
Jennifer Rozylo, Keren Mitchell, Mohammadali Nikoo, S. Elise Durante, Skye P. Barbic, Daniel Lin, Steve Mathias, Pouya Azar   +7 more
doaj   +1 more source

Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder - a case report

European Psychiatry
Introduction Opioid dependence is a complex condition that often requires long-term treatment and care. Methadone, a synthetic full opioid agonist, and buprenorphine, a partial agonist at the opioid receptor, are most commonly used for substitution ...
M. Delic
doaj   +1 more source

Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions

Western Journal of Emergency Medicine, 2022
Emergency departments (ED) are increasingly providing buprenorphine to persons with opioid use disorder. Buprenorphine programs in the ED have strong support from public health leaders and emergency medicine specialty societies and have proven to be ...
Timothy D. Kelly, Kathryn F. Hawk, Elizabeth A. Samuels, Reuben J. Strayer, Jason A. Hoppe   +4 more
doaj   +1 more source

Long‐term hippocampal alterations and cognitive impairment in a murine model of surgical sepsis

FEBS Open Bio, EarlyView.
Using a mouse model of surgical sepsis, we tested long‐term memory and analyzed the transcriptome of single cells isolated from the hippocampus. Survivor mice showed worse memory, loss of certain brain cell subpopulations, and abnormal immune cell activity—suggesting that post‐sepsis brain alterations may be linked to cognitive deficits.
Dong Seong Cho, Rebecca Schmitt, Aneesha Dasgupta, Alexandra Ducharme, Jason Doles   +4 more
wiley   +1 more source

Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study

Annals of Medicine, 2023
Background: At the start of the pandemic, relaxation of buprenorphine prescribing regulations created an opportunity to create new models of medications for opioid use disorder (MOUD) delivery and care.
Edward Suarez, Tyler S. Bartholomew, Marina Plesons, Katrina Ciraldo, Lily Ostrer, David P. Serota, Teresa A. Chueng, Morgan Frederick, Jason Onugha, Hansel E. Tookes   +9 more
doaj   +1 more source

Cyclic azapeptide CD36 ligand attenuates cardiac injury and reduces long‐chain fatty acid accumulation after myocardial ischemia–reperfusion in mice

FEBS Open Bio, EarlyView.
In a murine model of myocardial ischemia and reperfusion (MI/R), the CD36 azapeptide ligand MPE‐298 reduces cardiac injury and transiently lowers left ventricular long‐chain fatty acids (LCFAs) accumulation 3 h after reperfusion, accompanied by a decrease of oxidative stress and inflammation‐associated genes' expression in the heart and adipose tissue.
Jade Gauvin, Naghme Radmannia, David N. Huynh, Liliane Ménard, Caroline Daneault, Maïté Veilleux, Ahsanullah Ahsanullah, André C. Carpentier, William D. Lubell, Matthieu Ruiz, Huy Ong, Sylvie Marleau, Simon‐Pierre Gravel   +12 more
wiley   +1 more source

Low-dose buprenorphine initiation during pregnancy: a case report

AJOG Global Reports
Buprenorphine is recommended for pregnant patients with opioid use disorder. Traditional buprenorphine initiation requires moderate withdrawal symptoms to prevent precipitating withdrawal.
Shivania Reddy, BSc, Caitlin E. Martin, MD, MPH, FACOG, FASAM   +1 more
doaj   +1 more source

A Guide to Expanding the Use of Buprenorphine Beyond Standard Initiations for Opioid Use Disorder

Drugs in R&D, 2023
Buprenorphine has become an important medication in the context of the ongoing opioid epidemic. However, complex pharmacologic properties and varying government regulations create barriers to its use.
James C. Miller, Michael A. Brooks, Kelly E. Wurzel, Emily J. Cox, John F. Wurzel   +4 more
doaj   +1 more source